ArticleBMC public health2020
Global, regional, and national burdens of bladder cancer in 2017: estimates from the 2017 global burden of disease study.
Article in BMC public health, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.
- Psychological determinants of medication adherence in patients with hypertension: a systematic review and meta‑analysis.Journal of behavioral medicine · 2026Pooled it
- Prognostic Impact of the Gustave Roussy Immune Score on Cancer-Specific Survival and Treatment Completion in Patients with Bladder Cancer.Diagnostics (Basel, Switzerland) · 2026Article
- Global, regional, and national caries of permanent teeth incidence, prevalence, and disability-adjusted life years, 1990-2021: analysis for the global burden of disease study.BMC oral health · 2025Article
- Analysis of long-term trends and 15-year predictions of smoking-related bladder cancer burden in china across different age and sex groups from 1990 to 2021.Discover oncology · 2025Article
- Trends in the global, regional, and national burden of bladder cancer from 1990 to 2021: an observational study from the global burden of disease study 2021.Scientific reports · 2025Observational
- Contribution of smoking to the global burden of bladder cancer from 1990 to 2021 and projections to 2046.Tobacco induced diseases · 2025Article
- Challenges and opportunities in NMIBC management across Latin America: insights from healthcare providers and a patient advocacy group.Ecancermedicalscience · 2024Article
- Article
- Global, regional, and national burden of kidney, bladder, and prostate cancers and their attributable risk factors, 1990-2019.Military Medical Research · 2021Article
- Molecular Docking and Dynamics Simulation Revealed Ivermectin as Potential Drug againstMedicina (Kaunas, Lithuania) · 2021Article
- Vitamin A and Retinoids in Bladder Cancer Chemoprevention and Treatment: A Narrative Review of Current Evidence, Challenges and Future Prospects.International journal of molecular sciences · 2021Review
- High Concentration of Iopromide Induces Apoptosis and Autophagy in Human Embryonic Kidney CellsIn vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundThe aim of this study is to describe the prevalence and mortality of bladder cancer (BCa) using data obtained in the Global Burden of Disease study performed in 2017 (GBD 2017).
methodsData on BCa for 2017, including prevalence, mortality, and disability-adjusted life years (DALYs), were obtained from GBD 2017 at the global, regional, and national levels. We also analyzed the association of BCa burden with the country development level.
resultsThere were 2.63 million BCa cases estimated from the GBD 2017 data, with 200,000 persons dying of BCa, resulting in 3.60 million DALYs in 2017. The age-standardized prevalence (ASP) of BCa was 32.91/100,000 persons, and age-standardized death rate (ASDR) was 2.57/100,000 persons. The ASP and ASDR of BCa were higher in males than in females, and higher in people older than 60 years. The ASP and ASDR of BCa were higher in Western Europe and Central Europe than in South Asia, Andean Latin America, and Central Latin America, and higher in countries with a higher sociodemographic index (SDI). Correlation analysis identified that the ASP and ASDR of BCa were positively correlated with the country SDI (P < 0.0001 and ρ = 0.68 for ASP, and P = 0.0048 and ρ = 0.20 for ASDR). In addition, 33.72% deaths and 36.80% DALYs caused by BCa could be attributed to smoking globally.
conclusionThe prevalence and mortality of BCa were very high in 2017, especially in high-SDI countries. Smoking-cessation strategies should be strengthened to control the burden associated with BCa.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.